推薦產品
等級
pharmaceutical primary standard
API 家族
olanzapine
製造商／商標名
USP
應用
pharmaceutical (small molecule)
形式
neat
SMILES 字串
CN1CCN(CC1)C2=Nc3ccccc3Nc4sc(C)cc24
InChI
1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
InChI 密鑰
KVWDHTXUZHCGIO-UHFFFAOYSA-N
基因資訊
human ... DRD2(1813) , DRD3(1814) , DRD4(1815) , HTR2A(3356) , HTR2C(3358)
尋找類似的產品？ 前往 產品比較指南
相關類別
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Olanzapine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Olanzapine and Fluoxetine Capsules
- Olanzapine Orally Disintegrating Tablets
- Olanzapine Tablets
分析報告
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他說明
Sales restrictions may apply.
相關產品
產品號碼
描述
訂價
訊號詞
Danger
危險分類
Acute Tox. 3 Oral - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
標靶器官
Central nervous system
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
客戶也查看了
Rajendra P Shukla et al.
Journal of neural transmission (Vienna, Austria : 1996), 127(2), 291-299 (2020-01-08)
Olanzapine is a thienobenzodiazepine compound. It is one of the newer types of antipsychotic drugs used in the treatment of schizophrenia and other psychotic disorders. Several methods have been reported for analyzing olanzapine in its pure form or combined with
Mauricio Tohen et al.
Archives of general psychiatry, 60(11), 1079-1088 (2003-11-12)
Despite the longer duration of the depressive phase in bipolar disorder and the frequent clinical use of antidepressants combined with antipsychotics or mood stabilizers, relatively few controlled studies have examined treatment strategies for bipolar depression. To examine the use of
Jacqueline Flank et al.
Pediatric blood & cancer, 62(3), 496-501 (2014-10-21)
This retrospective review provides preliminary data regarding the safety and efficacy of olanzapine for chemotherapy-induced vomiting (CIV) control in children. Children <18 years old who received olanzapine for acute chemotherapy-induced nausea and vomiting (CINV) control from December 2010 to August
Hirotake Hida et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(3), 601-613 (2014-08-15)
Blonanserin differs from currently used serotonin 5-HT₂A/dopamine-D₂ receptor antagonists in that it exhibits higher affinity for dopamine-D₂/₃ receptors than for serotonin 5-HT₂A receptors. We investigated the involvement of dopamine-D₃ receptors in the effects of blonanserin on cognitive impairment in an
Karla Soares-Weiser et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 23(2), 118-125 (2012-05-29)
This comprehensive review and meta-analysis compared the effectiveness of olanzapine and other antipsychotics in schizophrenia treatment, defining effectiveness as time to all-cause medication discontinuation (primary) and as all-cause treatment discontinuation rates. This study examined randomized clinical trials (RCTs) and observational
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務
